Antiproliferative therapies, such as cyclin-dependent kinase (CDK ... The authors note that cell-cycle inhibitors suppress arthritis via different mechanisms to those of other RA therapies ...

Today, attention is turning to understand how non-proliferating cells, cells that have exited the cell cycle, retain their capacity to re-enter when necessary. In the past, this labs study of G1 ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

“We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on the tumor type,” said Vishnu Kumarasamy, PhD, first author on the new study ...

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation ... role of ATRX in senescence provides new insight ...

inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across ...

Incyclix Bio is a next-generation cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. The company's lead compound, INX-315, is a ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Cyclin-dependent kinase enzymes (CDKs) are of two types: cell cycle-regulating CDKs that participate ... (DRB), a ribonucleic acid polymerase II inhibitor, to analyze the consequences of CDK12 ...